CompletedNot Applicable

Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD

Hong Kong170 participantsStarted 2018-09-27

Plain-language summary

This study is a prospective study with a mean of 5-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development of clinical disorders in first-degree relatives (FDRs) of idiopathic REM Sleep Behavior Disorder (RBD) patients and healthy controls.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Chinese aged 40 or above;
✓. Being capable of giving informed consent for participation of the study;
✓. Sex-matched.

Exclusion criteria

✕. Younger than 40 years old (as the supposed neurodegenerative process may not have occurred);
✕. Not capable of giving informed consent for participation of the study.

What they're measuring

Changes of the overall probability of prodromal Parkinson's disease in the FDRs of patients with RBD.

Timeframe: Baseline and 5 years

Trial details

NCT IDNCT03671772

SponsorChinese University of Hong Kong

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-04-27

View on ClinicalTrials.gov More REM Sleep Behavior Disorder trials